Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Packet of azithromycin medication © Doctur4U

The ATOMIC2 trial, which was supported by the NIHR Oxford Biomedical Research Centre (BRC), was established to investigate if a common antibiotic called azithromycin could prevent patients with mild-moderate COVID-19 from getting worse.

Azithromycin is a safe, inexpensive and commonly prescribed antibiotic that is available worldwide. It has a wide range of antibacterial, anti-inflammatory and antiviral properties, but there were no strong data proving whether it was effective in COVID-19.

In the last few months, several trials have reported their results. Four trials have assessed the treatment in nearly 9,000 hospitalised patients and found no benefit from azithromycin in reducing the number of deaths or how long people stay in hospital.

Read the full story on the NIHR Oxford Biomedical Research Centre website

Similar stories

Eoghan Mulholland receives prestigious Lee Placito Research Fellowship

Awards and Appointments General

Dr Eoghan Mulholland has received the prestigious Lee Placito Research Fellowship in Gastrointestinal Cancer. Eoghan will use this 3-year position to research cell interactions in colorectal cancers.

Eleven Oxford professors honoured by the Academy of Medical Sciences

Awards and Appointments General

The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship.

3,400 different medicines used globally to treat COVID-19

Coronavirus COVID-19 General Research

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study.

Children and Adolescents’ Mental Health: One Year On

Coronavirus COVID-19 General Research

Parents and carers reported that behavioural, emotional and attentional difficulties in their children changed considerably throughout the past year, increasing in times of national lockdown and decreasing as restrictions eased and schools reopened, according to the latest Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) study, led by experts at the University of Oxford.

Tackling climate concerns through sustainable healthcare

General

A new initiative by Oxford Medical Students and faculty is accelerating the learning of sustainable healthcare at Oxford.